<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00775307</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-0703</org_study_id>
    <secondary_id>Eudract : 2008-004897-41</secondary_id>
    <nct_id>NCT00775307</nct_id>
  </id_info>
  <brief_title>Adjuvant Pazopanib in Stage I NSCLC</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase II-III Multi-centre Study to Evaluate the Effect of Adjuvant Pazopanib (GW786034) Versus Placebo on Post-surgical Disease-free Survival in Patients With Stage I Non Small Cell Lung Cancer and Tumor Size Equal or Inferior to 5 cm.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy and safety of pazopanib compared with&#xD;
      placebo in patients with T &lt; or = 5 cm, N0 (stage I according to TNM 2009) completely&#xD;
      resected NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in two phases as follows:&#xD;
&#xD;
        -  The Phase II component of the study will be a randomized, double-blind,&#xD;
           placebo-controlled, multi-centre study performed in France only. After undergoing NSCLC&#xD;
           resection, 140 patients will be randomized to receive either pazopanib 400 mg per day or&#xD;
           placebo for 24 weeks.&#xD;
&#xD;
        -  The Phase III component of the study will be a randomized, double-blind,&#xD;
           placebo-controlled, multi-centre study performed internationally. Patients who have&#xD;
           completed the Phase II component of the study will be followed and included in the Phase&#xD;
           III. Additional patients will also be recruited to a planned total of 355 patients per&#xD;
           treatment arm. New patients will be randomized to receive either pazopanib 400 mg per&#xD;
           day or placebo for 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 18, 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase II component of the study : Feasibility of regime ; Phase III component of the study : disease-free survival (DFS)</measure>
    <time_frame>month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS), Detailed assessment of compliance, Incidence and severity of AEs and other safety measures, Reporting profile of AEs of interest during long-term follow-up, Rates of loco-regional and distant recurrences, Quality of Life</measure>
    <time_frame>month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 400 mg/day (24 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pazopanib 400 mg/day (24 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAZOPANIB</intervention_name>
    <description>400 mg/day (24 weeks)</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 400 mg/day (24 weeks)</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Complete resection of the primary tumour and local extension has to be performed. All&#xD;
             margins must be free of microscopical disease. At the time of resection, a complete&#xD;
             mediastinal lymph-node resection or lymph-node sampling is required. Surgeons are&#xD;
             encouraged to dissect or sample all accessible nodal levels.&#xD;
&#xD;
          2. Single surgically resected pathological stage I NSCLC lesion: consisting of a tumor &lt;&#xD;
             5 cm in greatest dimension (see TNM staging on Appendix 10).&#xD;
&#xD;
          3. No regional lymph node involvement.&#xD;
&#xD;
          4. Pre-operative petscan&#xD;
&#xD;
          5. Satisfactory healing of surgical wound.&#xD;
&#xD;
          6. Patients &gt;= 18 and &lt; 70 years of age.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.&#xD;
&#xD;
          8. Recruited to the study and available to start treatment investigational product at&#xD;
             least 4 weeks but no longer that 8 weeks after the surgical resection of the NSCLC.&#xD;
&#xD;
          9. No approved or investigational anti-cancer therapy concurrently or in the 5 years&#xD;
             prior to start of study drug, including tumor embolization, chemotherapy, radiation&#xD;
             therapy, immunotherapy, hormone therapy, biologic therapy, or anti angiogenic therapy&#xD;
             (e.g., inhibitors of VEGF or VEGFR).&#xD;
&#xD;
         10. Adequate organ system function&#xD;
&#xD;
         11. Ability to swallow and retain oral medication.&#xD;
&#xD;
         12. 12. A female is eligible to enter and participate in this study if she is of:&#xD;
&#xD;
             Non-childbearing potential (i.e., physiologically incapable of becoming pregnant),&#xD;
             including any female who has undergone:&#xD;
&#xD;
               -  Hysterectomy.&#xD;
&#xD;
               -  Bilateral oophorectomy (ovariectomy).&#xD;
&#xD;
               -  Bilateral tubal ligation.&#xD;
&#xD;
               -  Or who is post-menopausal:&#xD;
&#xD;
               -  Patients not using hormone replacement therapy (HRT) must have experienced total&#xD;
                  cessation of menses for ≥1 year and be greater than 45 years in age, OR, in&#xD;
                  questionable cases, have a follicle stimulating hormone value &gt;40 mIU/mL and an&#xD;
                  estradiol value &lt;40 pg/mL (&lt;140 pmol/L).&#xD;
&#xD;
               -  Subject using HRT must have experienced total cessation of menses for ≥ 1 year&#xD;
                  and be greater than 45 years of age OR have had documented evidence of menopause&#xD;
                  based on FSH and estradiol concentrations prior to initiation of HRT.&#xD;
&#xD;
             Childbearing potential, including any female who has had a negative serum pregnancy&#xD;
             test within 1 week prior to the first dose of study treatment, preferably as close to&#xD;
             the first dose as possible, and agrees to use adequate contraception. Contraceptive&#xD;
             methods acceptable to the IFCT, when used consistently and in accordance with both the&#xD;
             product label and the instructions of the physician, are as follow:&#xD;
&#xD;
               -  An intrauterine device with a documented failure rate of less than 1% per year.&#xD;
&#xD;
               -  Male partner sterilization (vasectomy with documentation of azoospermia) prior to&#xD;
                  the female subject's entry and is the sole sexual partner for that female.&#xD;
&#xD;
               -  Complete abstinence from sexual intercourse for 14 days before exposure to&#xD;
                  investigational product, through the dosing period, and for at least 21 days&#xD;
                  after the last dose of investigational product.&#xD;
&#xD;
               -  Double-barrier contraception : condom and an occlusive cap (diaphragm or&#xD;
                  cervical/vault caps) with a vaginal spermicidal agent&#xD;
                  (foam/gel/film/cream/suppository)&#xD;
&#xD;
               -  Oral contraceptive, either combined or progestogen alone [Hatcher, 2004]&#xD;
&#xD;
               -  Injectable progestogen [Hatcher, 2004]&#xD;
&#xD;
               -  Implant of levonorgestrel [Hatcher, 2004]&#xD;
&#xD;
               -  Estrogenic vaginal ring [Hatcher, 2004]&#xD;
&#xD;
               -  Percutaneous contraceptive patches [Hatcher, 2004]&#xD;
&#xD;
             Female patients who are lactating should discontinue nursing prior to the first dose&#xD;
             of study drug and should refrain from nursing throughout the treatment period and for&#xD;
             15 days following the last dose of study drug.&#xD;
&#xD;
             A male with a female partner of childbearing potential is eligible to enter and&#xD;
             participate in the study if he uses a barrier method of contraception or abstinence&#xD;
             during the study.&#xD;
&#xD;
         13. French Patients: in France, a patient will be eligible for inclusion in this study&#xD;
             only if either affiliated to or a beneficiary of a social security insurance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior malignancy. Note: Patients who have had another malignancy and were treated more&#xD;
             than 5 years ago and have since been considered cured, or patients with a history of&#xD;
             basocellular skin carcinoma or in situ carcinoma of the uterine cervix are eligible.&#xD;
&#xD;
          2. Presence of any concurrent disease or condition that would make the subject&#xD;
             inappropriate for study participation including any unresolved or unstable, serious&#xD;
             toxicity from prior administration of another investigational drug or any serious&#xD;
             medical disorder that would interfere with the subject's safety, obtaining informed&#xD;
             consent, or compliance with all study related procedures.&#xD;
&#xD;
          3. Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks&#xD;
             prior to beginning therapy, or anticipation of the need for a major surgical procedure&#xD;
             during the course of the study.&#xD;
&#xD;
          4. History or clinical evidence of nodal or distant metastases (screening of brain&#xD;
             metastasis is mandatory).&#xD;
&#xD;
          5. Bronchioalveolar carcinoma of lobar or multi lobar involvement. Bronchioalveolar&#xD;
             carcinomas presenting as a discrete solitary radiological mass or nodule are eligible.&#xD;
&#xD;
          6. History of human immunodeficiency virus infection or chronic hepatitis B or C.&#xD;
&#xD;
          7. History of hemoptysis after resection of lung cancer.&#xD;
&#xD;
          8. Clinically significant gastrointestinal anomalies including, but not limited to:&#xD;
&#xD;
               -  Malabsorption syndrome&#xD;
&#xD;
               -  Disease significantly affecting gastrointestinal function or major resection of&#xD;
                  the stomach or small bowel that could affect the absorption of study drug.&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Ulcerative colitis, erosive esophagitis or gastritis, infectious or inflammatory&#xD;
                  bowel disease, diverticulitis or other gastrointestinal condition increasing the&#xD;
                  risk of perforation.&#xD;
&#xD;
               -  History of abdominal fistula, gastrointestinal perforation, or intra abdominal&#xD;
                  abscess within 28 days prior to beginning study treatment&#xD;
&#xD;
          9. Presence of active or uncontrolled infection.&#xD;
&#xD;
         10. Evidence of active bleeding or bleeding diathesis.&#xD;
&#xD;
         11. History of any one or more of the following cardiovascular conditions within the past&#xD;
             6 months:&#xD;
&#xD;
               -  Coronary/peripheral artery bypass graft, cardiac angioplasty or stenting.&#xD;
&#xD;
               -  Myocardial infarction.&#xD;
&#xD;
               -  Severe/unstable angina pectoris.&#xD;
&#xD;
               -  Symptomatic peripheral vascular disease, pulmonary embolism or untreated deep&#xD;
                  venous thrombosis (DVT), cerebrovascular accident or transient ischemic attack.&#xD;
&#xD;
             Note : Subject with recent DVT who have been treated with therapeutic anti-coagulating&#xD;
             agents for at least 6 weeks are eligible&#xD;
&#xD;
             • Class III or IV congestive heart failure, as defined by the New York Heart&#xD;
             Association (Appendix 5).&#xD;
&#xD;
         12. Poorly controlled hypertension (defined as a systolic blood pressure (SBP) of &gt;= 140&#xD;
             mmHg or diastolic blood pressure (DBP) &gt;= 90 mmHg.&#xD;
&#xD;
             Note: Initiation or adjustment of anti-hypertensive medication(s) is permitted prior&#xD;
             to study entry. Blood pressure (BP) must be re-assessed on two occasions separated by&#xD;
             at least 5 minutes. The mean SBP/DBP values from both BP assessments must be &lt;140/90&#xD;
             mmHg in order for a subject to be eligible for the study.&#xD;
&#xD;
         13. Following anomalies on ECG : Q wave, ischemia, QT &gt; 480 msec, atrio-ventricular block&#xD;
             2 or 3, atrial fibrillation&#xD;
&#xD;
         14. Therapeutic anticoagulation treatment.&#xD;
&#xD;
         15. Chronic daily treatment with aspirin (≥ 325 mg/day) or non-steroidal anti-inflammatory&#xD;
             agents known to inhibit platelet function. Treatment with dipyridamole, ticlopidine,&#xD;
             clopidogrel and/or cilostazol is also not allowed.&#xD;
&#xD;
         16. Pregnant or lactating female.&#xD;
&#xD;
         17. Concurrent treatment with an investigational agent or participation in another&#xD;
             clinical trial.&#xD;
&#xD;
         18. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to pazopanib.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin BESSE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Gustave Roussy (IGR)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Charles SORIA, Pr</last_name>
    <role>Study Director</role>
    <affiliation>Institut Gustave Roussy (IGR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Annemasse - CH</name>
      <address>
        <city>Ambilly</city>
        <zip>74100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bobigny - Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bordeaux - Polyclinique Nord</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boulogne - Ambroise Paré</name>
      <address>
        <city>Boulogne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Béziers - CH</name>
      <address>
        <city>Béziers</city>
        <zip>34525</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caen - Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caen - CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clamart - Hôpital Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clermont Ferrand - CHU</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colmar - CH</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dax - CH</name>
      <address>
        <city>Dax</city>
        <zip>40107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grenoble - CHU</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Le Mans - Centre Hospitalier</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lille - Hôpital Calmette</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mantes La Jolie - CH</name>
      <address>
        <city>Mantes La Jolie</city>
        <zip>78200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille - Hôpital Sainte Marguerite</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metz - Clinique Claude Bernard</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mont de Marsan - CH</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montpellier - Clinique Clémentville</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montpellier - CHRU</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moulins - CH</name>
      <address>
        <city>Moulins</city>
        <zip>03000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes - Centre René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevers - CH</name>
      <address>
        <city>Nevers</city>
        <zip>58033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orléans - CH</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris - Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris - hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris - Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pau - CH</name>
      <address>
        <city>Pau</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catalan d'Onologie</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reims - CHU</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rennes - CHU</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strasbourg - NHC</name>
      <address>
        <city>Strasbourg</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thonon les bains - CH</name>
      <address>
        <city>Thonon les bains</city>
        <zip>74200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulon - HIA</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulouse - CHU Larrey</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nancy - CHU</name>
      <address>
        <city>Vandoeuvre lès Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vesoul - CHI</name>
      <address>
        <city>Vesoul</city>
        <zip>70000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Villejuif - Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ifct.fr</url>
    <description>IFCT official website</description>
  </link>
  <results_reference>
    <citation>Besse B, Mazières J, Ribassin-Majed L, Barlesi F, Bennouna J, Gervais R, Moreau L, Berard H, Debieuvre D, Molinier O, Moro-Sibilot D, Souquet PJ, Jacquot S, Petit L, Lena H, Pignon JP, Lacas B, Morin F, Milleron B, Zalcman G, Soria JC; Intergroupe Francophone de Cancérologie Thoracique (IFCT). Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial. Ann Oncol. 2017 May 1;28(5):1078-1083. doi: 10.1093/annonc/mdx070.</citation>
    <PMID>28327934</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 17, 2008</study_first_submitted>
  <study_first_submitted_qc>October 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2008</study_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Stage I</keyword>
  <keyword>adjuvant therapy</keyword>
  <keyword>Adjuvant Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

